Polycythemia vera market to expand with 9 new therapies entering by 2036, led by rusfertide and givinostat.

The polycythemia vera market is expected to grow significantly by 2036, driven by nine key companies developing new treatments such as rusfertide, givinostat, and bomedemstat. Current treatments focus on managing symptoms and disease progression, but new therapies aim to improve patient outcomes and reduce reliance on phlebotomy. Rusfertide, developed by Protagonist Therapeutics and Takeda, is poised to launch soon, potentially reshaping treatment approaches. Other promising candidates like givinostat and bomedemstat are in late-stage trials, signaling a transformative shift in managing this chronic blood disorder.